{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:44:12Z","timestamp":1789839852392,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Faculty of Health Sciences, Jagiellonian University Medical College","award":["K\/ZDS\/006281"],"award-info":[{"award-number":["K\/ZDS\/006281"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12640-017-9759-0","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T06:00:58Z","timestamp":1496383258000},"page":"544-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents"],"prefix":"10.1007","volume":"32","author":[{"given":"Piotr","family":"Popik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ho\u0142uj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Librowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"9759_CR1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.encep.2013.11.002","volume":"41","author":"G Ammar","year":"2015","unstructured":"Ammar G, Naja WJ, Pelissolo A (2015) Treatment-resistant anxiety disorders: a literature review of drug therapy strategies. Enc\u00e9phale 41:260\u2013265","journal-title":"Enc\u00e9phale"},{"key":"9759_CR2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00213-011-2169-8","volume":"215","author":"AJ Bechtholt-Gompf","year":"2011","unstructured":"Bechtholt-Gompf AJ, Smith KL, John CS et al (2011) CD-1 and Balb\/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology 215:689\u2013695","journal-title":"Psychopharmacology"},{"key":"9759_CR3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351\u2013354","journal-title":"Biol Psychiatry"},{"key":"9759_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-002-1155-6","volume":"163","author":"F Borsini","year":"2002","unstructured":"Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121\u2013141","journal-title":"Psychopharmacology"},{"key":"9759_CR5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pbb.2005.04.015","volume":"81","author":"M Bourin","year":"2005","unstructured":"Bourin M, Masse F, Dailly E et al (2005) Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. Pharmacol Biochem Behav 81:645\u2013656","journal-title":"Pharmacol Biochem Behav"},{"key":"9759_CR6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-2999(86)90051-8","volume":"126","author":"CL Broekkamp","year":"1986","unstructured":"Broekkamp CL, Rijk HW, Joly Gelouin D et al (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim- induced grooming in mice. Eur J Pharmacol 126:223\u2013229","journal-title":"Eur J Pharmacol"},{"key":"9759_CR7","unstructured":"Burgdorf J, Zhang XL, Nicholson KL, et al (2013) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38"},{"key":"9759_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-3565(25)28311-2","volume":"168","author":"G Chen","year":"1969","unstructured":"Chen G, Ensor CR, Bohner B (1969) The pharmacology of 2-(ethylamino)-2-(2-thienyl)-cyclohexanone-HCl (CI-634). J Pharmacol Exp Ther 168:171\u2013179","journal-title":"J Pharmacol Exp Ther"},{"key":"9759_CR9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678\u2013684","journal-title":"Anesthesiology"},{"key":"9759_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","volume":"31","author":"A Ennaceur","year":"1988","unstructured":"Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain res 31:47\u201359","journal-title":"Behav Brain res"},{"key":"9759_CR11","doi-asserted-by":"crossref","unstructured":"Eskelund A, Li Y, Budac DP, et al (2017) Drugs with antidepressant properties affect tryptophan metabolites differently in rodent models with depression-like behavior. J Neurochem","DOI":"10.1111\/jnc.14043"},{"key":"9759_CR12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0022-3565(25)39310-9","volume":"243","author":"JM ffRench-Mullen","year":"1987","unstructured":"ffRench-Mullen JM, Lehmann J, Bohacek R et al (1987) Tiletamine is a potent inhibitor of N-methyl-aspartate-induced depolarizations in rat hippocampus and striatum. J Pharmacol ExpTher 243:915\u2013920","journal-title":"J Pharmacol ExpTher"},{"key":"9759_CR13","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1093\/ilar.53.1.55","volume":"53","author":"S Gargiulo","year":"2012","unstructured":"Gargiulo S, Greco A, Gramanzini M et al (2012) Mice anesthesia, analgesia, and care, part I: anesthetic considerations in preclinical research. ILAR j 53:E55\u2013E69","journal-title":"ILAR j"},{"key":"9759_CR14","doi-asserted-by":"crossref","unstructured":"Glue P, Medlicott NJ, Harland S, et al (2017) Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol: 269881117705089","DOI":"10.1177\/0269881117705089"},{"key":"9759_CR15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181\u20131197","journal-title":"J Psychopharmacol"},{"key":"9759_CR16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00008877-199505001-00026","volume":"6","author":"I Gyertyan","year":"1995","unstructured":"Gyertyan I (1995) Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol 6:24\u201331","journal-title":"Behav Pharmacol"},{"key":"9759_CR17","first-page":"1","volume":"7","author":"T Hayase","year":"2006","unstructured":"Hayase T, Yamamoto Y, Yamamoto K (2006) Behavioral effects of ketamine and toxic interactions with psychostimulants. BMCNeurosci 7:1\u201310","journal-title":"BMCNeurosci"},{"key":"9759_CR18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FBP.0000000000000132","volume":"26","author":"M Holuj","year":"2015","unstructured":"Holuj M, Popik P, Nikiforuk A (2015) Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors. Behav Pharmacol 26:766\u2013775","journal-title":"Behav Pharmacol"},{"key":"9759_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","volume":"224","author":"H Koike","year":"2011","unstructured":"Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain res 224:107\u2013111","journal-title":"Behav Brain res"},{"key":"9759_CR20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","volume":"206","author":"J Kornhuber","year":"1991","unstructured":"Kornhuber J, Bormann J, Hubers M et al (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297\u2013300","journal-title":"Eur J Pharmacol"},{"key":"9759_CR21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.npp.1301133","volume":"32","author":"E Koros","year":"2007","unstructured":"Koros E, Rosenbrock H, Birk G et al (2007) The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology 32:562\u2013576","journal-title":"Neuropsychopharmacology"},{"key":"9759_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch gen Psychiatry 51:199\u2013214","journal-title":"Arch gen Psychiatry"},{"key":"9759_CR23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.lfs.2005.08.002","volume":"78","author":"X Li","year":"2006","unstructured":"Li X, Morrow D, Witkin JM (2006) Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 78:1933\u20131939","journal-title":"Life Sci"},{"key":"9759_CR24","first-page":"363","volume":"81","author":"ED Luby","year":"1959","unstructured":"Luby ED (1959) Study of a new schizophrenomimetic drug\u2014Sernyl. AMAArchNeurolPsychiat 81:363\u2013369","journal-title":"AMAArchNeurolPsychiat"},{"key":"9759_CR25","first-page":"56","volume":"159","author":"DA Luckenbaugh","year":"2014","unstructured":"Luckenbaugh DA, Niciu MJ, Ionescu DF et al (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? J AffectDisord 159:56\u201361","journal-title":"J AffectDisord"},{"key":"9759_CR26","doi-asserted-by":"crossref","unstructured":"Marinova Z, Chuang DM, Fineberg N (2017) Glutamate-modulating drugs as a potential therapeutic strategy in obsessive-compulsive disorder. Curr Neuropharmacol","DOI":"10.2174\/1570159X15666170320104237"},{"key":"9759_CR27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/dta.1620","volume":"6","author":"H Morris","year":"2014","unstructured":"Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614\u2013632","journal-title":"Drug Test Anal"},{"key":"9759_CR28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/13543784.2014.852536","volume":"23","author":"JR Moskal","year":"2014","unstructured":"Moskal JR, Burch R, Burgdorf JS et al (2014) GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 23:243\u2013254","journal-title":"Expert Opin Investig Drugs"},{"key":"9759_CR29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.biopsych.2016.07.005","volume":"80","author":"JW Murrough","year":"2016","unstructured":"Murrough JW (2016) Ketamine for depression: an update. Biol Psychiatry 80:416\u2013418","journal-title":"Biol Psychiatry"},{"key":"9759_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.psyneuen.2013.11.009","volume":"40","author":"A Nikiforuk","year":"2014","unstructured":"Nikiforuk A, Popik P (2014) Ketamine prevents stress-induced cognitive inflexibility in rats. Psychoneuroendocrinology 40:119\u2013122","journal-title":"Psychoneuroendocrinology"},{"key":"9759_CR31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0269881113480991","volume":"27","author":"A Nikiforuk","year":"2013","unstructured":"Nikiforuk A, Fijal K, Potasiewicz A et al (2013a) The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats. J Psychopharmacol 27:469\u2013476","journal-title":"J Psychopharmacol"},{"key":"9759_CR32","doi-asserted-by":"crossref","first-page":"e66695","DOI":"10.1371\/journal.pone.0066695","volume":"8","author":"A Nikiforuk","year":"2013","unstructured":"Nikiforuk A, Kos T, Fijal K et al (2013b) Effects of the selective 5-HT7 receptor antagonist SB-269970, and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One 8:e66695","journal-title":"PLoS One"},{"key":"9759_CR33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0091-3057(91)90590-X","volume":"38","author":"K Njung'e","year":"1991","unstructured":"Njung'e K, Handley SL (1991) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38:63\u201367","journal-title":"Pharmacol Biochem Behav"},{"key":"9759_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FBP.0000000000000259","volume":"28","author":"M Papp","year":"2017","unstructured":"Papp M, Gruca P, Lason-Tyburkiewicz M et al (2017) Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression. Behav Pharmacol 28:1\u20138","journal-title":"Behav Pharmacol"},{"key":"9759_CR35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1213\/00000539-199804000-00027","volume":"86","author":"A Plesan","year":"1998","unstructured":"Plesan A, Hedman U, Xu XJ et al (1998) Comparison of ketamine and dextromethorphan in potentiating the antinociceptive effect of morphine in rats. Anesth Analg 86:825\u2013829","journal-title":"Anesth Analg"},{"key":"9759_CR36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00213-008-1158-z","volume":"198","author":"P Popik","year":"2008","unstructured":"Popik P, Kos T, Sowa-Kucma M et al (2008) Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology 198:421\u2013430","journal-title":"Psychopharmacology"},{"key":"9759_CR37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","volume":"266","author":"RD Porsolt","year":"1977","unstructured":"Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730\u2013732","journal-title":"Nature"},{"key":"9759_CR38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neuropharm.2016.10.002","volume":"113","author":"A Potasiewicz","year":"2017","unstructured":"Potasiewicz A, Holuj M, Kos T et al (2017) 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the alpha7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats. Neuropharmacology 113:188\u2013197","journal-title":"Neuropharmacology"},{"key":"9759_CR39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","volume":"28","author":"SH Preskorn","year":"2008","unstructured":"Preskorn SH, Baker B, Kolluri S et al (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631\u2013637","journal-title":"J Clin Psychopharmacol"},{"key":"9759_CR40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1081\/CLT-100105161","volume":"39","author":"MT Quail","year":"2001","unstructured":"Quail MT, Weimersheimer P, Woolf AD et al (2001) Abuse of telazol: an animal tranquilizer. J Toxicol Clin Toxicol 39:399\u2013402","journal-title":"J Toxicol Clin Toxicol"},{"key":"9759_CR41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1471-4159.1991.tb02005.x","volume":"56","author":"TS Rao","year":"1991","unstructured":"Rao TS, Contreras PC, Cler JA et al (1991) Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sites. J Neurochem 56:890\u2013897","journal-title":"J Neurochem"},{"key":"9759_CR42","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A et al (2013) Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38:2475\u20132483","journal-title":"Neuropsychopharmacology"},{"key":"9759_CR43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pharep.2014.11.003","volume":"67","author":"K Salat","year":"2015","unstructured":"Salat K, Podkowa A, Kowalczyk P et al (2015a) Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression. Pharmacol rep 67:465\u2013472","journal-title":"Pharmacol rep"},{"key":"9759_CR44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pharep.2015.04.018","volume":"67","author":"K Salat","year":"2015","unstructured":"Salat K, Podkowa A, Mogilski S et al (2015b) The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice. Pharmacol Rep 67:1155\u20131162","journal-title":"Pharmacol Rep"},{"key":"9759_CR45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2015.07.037","volume":"99","author":"K Salat","year":"2015","unstructured":"Salat K, Siwek A, Starowicz G et al (2015c) Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology 99:301\u2013307","journal-title":"Neuropharmacology"},{"key":"9759_CR46","first-page":"211","volume":"18","author":"F Sams-Dodd","year":"2013","unstructured":"Sams-Dodd F (2013) Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug DiscovToday 18:211\u2013217","journal-title":"Drug DiscovToday"},{"key":"9759_CR47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.ajp.2014.13101434","volume":"171","author":"AF Schatzberg","year":"2014","unstructured":"Schatzberg AF (2014) A word to the wise about ketamine. Am J Psychiatry 171:262\u2013264","journal-title":"Am J Psychiatry"},{"key":"9759_CR48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.psyneuen.2007.04.003","volume":"32","author":"T Schneider","year":"2007","unstructured":"Schneider T, Popik P (2007) Attenuation of estrous cycle-dependent marble burying in female rats by acute treatment with progesterone and antidepressants. Psychoneuroendocrinology 32:651\u2013659","journal-title":"Psychoneuroendocrinology"},{"key":"9759_CR49","first-page":"29","volume":"5","author":"JS Silvestre","year":"1997","unstructured":"Silvestre JS, Nadal R, Pallares M et al (1997) Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. DepressAnxiety 5:29\u201333","journal-title":"DepressAnxiety"},{"key":"9759_CR50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-979537","volume":"29","author":"P Skolnick","year":"1996","unstructured":"Skolnick P, Layer RT, Popik P et al (1996) Adaptation of the N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23\u201326","journal-title":"Pharmacopsychiatry"},{"key":"9759_CR51","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/sj.npp.1300532","volume":"29","author":"T Strekalova","year":"2004","unstructured":"Strekalova T, Spanagel R, Bartsch D et al (2004) Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 29:2007\u20132017","journal-title":"Neuropsychopharmacology"},{"key":"9759_CR52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rvsc.2017.03.011","volume":"114","author":"LX Su","year":"2017","unstructured":"Su LX, Shi XX, Yang P et al (2017) Effects of tiletamine on the adenosine monophosphate-activated protein kinase signaling pathway in the rat central nervous system. Res vet Sci 114:101\u2013108","journal-title":"Res vet Sci"},{"key":"9759_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","volume":"185","author":"R Trullas","year":"1990","unstructured":"Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1\u201310","journal-title":"Eur J Pharmacol"},{"key":"9759_CR54","doi-asserted-by":"publisher","unstructured":"Yang C, Qu Y, Abe M et al (2017) (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry. doi: 10.1016\/j.biopsych.2016.12.020","DOI":"10.1016\/j.biopsych.2016.12.020"},{"key":"9759_CR55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ et al (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481\u2013486","journal-title":"Nature"},{"key":"9759_CR56","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ et al (2006a) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch gen Psychiatry 63:856\u2013864","journal-title":"Arch gen Psychiatry"},{"key":"9759_CR57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","volume":"163","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Quiroz JA et al (2006b) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153\u2013155","journal-title":"Am J Psychiatry"},{"key":"9759_CR58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neulet.2016.12.070","volume":"639","author":"X Zhu","year":"2017","unstructured":"Zhu X, Ye G, Wang Z et al (2017) Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats. Neurosci Lett 639:132\u2013137","journal-title":"Neurosci Lett"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12640-017-9759-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-017-9759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-017-9759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:40:38Z","timestamp":1750286438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12640-017-9759-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["9759"],"URL":"https:\/\/doi.org\/10.1007\/s12640-017-9759-0","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}